This Patient Does NOT Have COPD
Based on the spirometry results showing an FEV1/FVC ratio of 73% (above the 70% threshold), this patient does not meet diagnostic criteria for COPD and should not be diagnosed or treated as such 1.
Diagnostic Interpretation
The spirometry results show:
- FEV1/FVC ratio: 73% - This is ABOVE the 0.70 (70%) threshold required for COPD diagnosis
- FEV1: 75% predicted (mildly reduced)
- FVC: 77% predicted (mildly reduced)
According to GOLD 2025 guidelines, post-bronchodilator FEV1/FVC <0.7 is required to confirm COPD diagnosis 1. This patient's ratio of 0.73 does not meet obstruction criteria.
What This Patient Actually Has: PRISm
This patient has Preserved Ratio Impaired Spirometry (PRISm) - defined as FEV1/FVC ≥0.7 with FEV1 <80% predicted 2, 3. This is a distinct entity from COPD that affects 2.4-16.7% of the population globally and is commonly misclassified as obstructive airway disease 2, 3.
Key Characteristics of PRISm:
- More common in individuals with metabolic comorbidities, smoking history, female sex, and higher BMI 3
- Associated with increased respiratory symptoms and cardiovascular events 3
- 22-80% of PRISm patients are inappropriately prescribed inhaled medications for presumed obstructive disease 2
- Heterogeneous condition that can transition to other spirometric categories over time, including progression to obstruction 3
Critical Pitfall to Avoid
Do NOT diagnose this patient with COPD based on smoking history alone. The 30-pack-year history and age are risk factors, but spirometry must demonstrate obstruction (FEV1/FVC <0.7 post-bronchodilator) to confirm diagnosis 1, 4. Misclassification leads to inappropriate inhaled medication use and incorrect prognostication 2.
Recommended Management Algorithm
1. Confirm Spirometry Quality
- Ensure post-bronchodilator measurements were obtained (if not, repeat with bronchodilator) 1
- GOLD 2025 recommends using pre-BD spirometry to rule out COPD and post-BD to confirm diagnosis 1
2. Smoking Cessation (Priority #1)
- Immediate smoking cessation counseling with behavioral and pharmacological therapies 4
- This is the single most important intervention for preventing progression to COPD and reducing mortality
3. Address PRISm-Specific Risk Factors
- Evaluate and manage metabolic comorbidities (diabetes, obesity) 3
- Screen for cardiovascular disease given increased risk 3
- Assess for actionable traits: emphysema on CT, interstitial lung abnormalities 3
4. Longitudinal Monitoring
- Repeat spirometry in 12 months to assess for progression 5
- Up to one-third of patients can shift diagnostic categories within 1-2 years 5
- Monitor for development of post-BD obstruction, as some PRISm patients progress to COPD 3
5. Symptom Assessment
- Evaluate for respiratory symptoms (dyspnea, cough, sputum production)
- If symptomatic, investigate alternative causes beyond COPD (cardiac disease, deconditioning, obesity-related restriction) 2
What NOT to Do
- Do NOT prescribe inhaled bronchodilators or corticosteroids - there is no evidence supporting their use in PRISm without obstruction 2
- Do NOT label this patient as having COPD - this creates inappropriate treatment expectations and potential insurance/employment implications
- Do NOT ignore the mildly reduced lung function - PRISm carries increased mortality and cardiovascular risk requiring attention 3
Age Consideration
At 74 years old, be aware that the fixed 0.70 ratio may slightly overdiagnose obstruction in elderly patients 6, 7. However, this patient's ratio of 0.73 is clearly above threshold regardless of age-related considerations, making the non-obstructed classification robust.